XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
X4 Pharmaceuticals, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.75+0.16 (+6.18%)
Close on Oct 19, 2026
- Market cap
- $347.45M
- P/E (TTM)
- –
- Dividend yield
- –
X4 Pharmaceuticals, Inc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| License and other revenue | $28.59M | $0 | $0 | – | – | 439.8% | – |
| Product revenue, net | $6.52M | $2.56M | $0 | – | – | 100.4% | +155.1% |
By region
From the segment and revenue-disaggregation notes of X4 Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.